Poster Abstract Session:
135. Clinical Trials
Friday, October 9, 2015: 12:30 PM-2:00 PM
Room: Poster Hall

Learning Objectives:

-

Tracks: Investigative ID

Presentations:
888
Clinical use of a prediction rule to guide admission policy in community-acquired invasive urinary tract infection: a randomized clinical trial
J.E. Stalenhoef, MD ; C. Van Nieuwkoop, MD, PhD ; A.M. Vollaard, MD, PhD ; W.E. Van Der Starre, MD ; N.M. Delfos, MD ; E.M.S. Leyten, MD, PhD ; T. Koster, MD, PhD ; H.C. Ablij, MD ; J.W. Van 't Wout, MD, PhD ; J.T. Van Dissel, MD, PhD
889
Effectiveness of Implementing Take-Home Kits for Specimen Collection in a Clinical Trial
Jenna Los, MLA ; Mary Bessesen, MD ; Alexandria C Brown, PhD ; Derek Cummings, PhD ; Charlotte Gaydos, DrPH, FIDSA ; Cynthia Gibert, MD, MSc, FIDSA ; Geoffrey Gorse, MD, FIDSA ; Jeffrey Holden, MA ; Ann-Christine Nyquist, MD, MSPH, FPIDS ; Connie S. Price, MD ; Lewis J. Radonovich, MD ; Nicholas G Reich, PhD ; Maria C. Rodriguez-Barradas, MD, FIDSA ; Michael S. Simberkoff, MD, FIDSA ; Trish M. Perl, MD, MSc, FIDSA, FSHEA
Posters
  • Los_THKs_poster2.pdf (2.7 MB)
  • 890
    Barriers and Motivators to Participation in HIV clinical trials of Persons Living with HIV (PLHIV) in the Southern United States (US)
    Prema Menezes, Ph D ; Kea Turner, MPH ; Jessica Margolis, BS ; Cheryl Marcus, MSN ; Joseph Eron, MD ; Randall Teal, MA
    892
    Cost Drivers of Hospital Acquired Bacterial Pneumonia and Ventilator Associated Bacterial Pneumonia (HABP/VABP) Phase Three Clinical Trials
    Stella Stergiopoulos, BA ; Pamela Tenaerts, MD ; Kenneth Getz, MBA ; Carrie Brown, MS ; Josephine Awatin, BS ; Sara Calvert, PhD ; Joseph Dimasi, PhD
    893
    Characterization of Mycoplasma pneumoniae Infection and Outcomes in the SOLITAIRE-Oral, Global Phase 3 Clinical Trial for Solithromycin
    David Oldach, MD, FIDSA ; Hristo Metev, MD ; Analia Mykietiuk, MD ; Cristina Mihaela Tanaseanu, MD ; Anita Das, PhD ; Brian Jamieson, MD ; Kay Clark, RN ; Amanda Sheets, PhD ; Kara Keedy, PhD ; Donna Crabb, MT(ASCP) ; Amy Ratliff, MLS (ASCP) ; Ken Waites, MD ; Prabhavathi Fernandes, PhD
    894
    Detection of Pneumococcal Pneumonia in a Phase 3 Trial Comparing Oral Solithromycin versus Oral Moxifloxacin for Treatment of Community-acquired Bacterial Pneumonia in Adults
    Sopio Chochua, MD, PhD, MSCR ; Amanda Sheets, PhD ; Kara Keedy, PhD ; Brian Jamieson, MD ; David Oldach, MD, FIDSA ; Prabhavathi Fernandes, PhD ; Anita Das, PhD ; Keith Klugman, MD, PhD, FIDSA ; Jorge Vidal, PhD
    895
    Quantitation of Clostridium difficile in Patients with First Episode Infection following Fidaxomicin or Vancomycin
    Seth T. Housman, PharmD, MPA ; Abrar Thabit, PharmD ; Joseph Kuti, PharmD ; Richard Quintiliani, MD ; David P. Nicolau, PharmD, FCCP, FIDSA
    896
    Does Rifaximin Chemoprophylaxis Prevent Campylobacteriosis in the Human Challenge Model?
    Clayton D. Harro, MD, ScM ; Joanna E. Rimmer, MBChB, DTM&H ; David Sack, MD ; Kawsar R. Talaat, MD ; Ramiro L. Gutierrez, MD, MPH ; Barbara Denearing, RN, BSN, CCRC ; Chad K. Porter, Ph.D., MPH ; Jessica Brubaker, M.S. ; Alexander C. Maue, Ph.D. ; Renee M. Laird, Ph.D. ; Frederic Poly, Ph.D. ; Patricia Guerry, Ph.D. ; Kayla Jaep, B.S. ; Ashley Alcala, B.S. ; David R. Tribble, MD, DrPH, FIDSA ; Mark S. Riddle, MD, DrPH
    Posters
  • IDSA poster_final draft.pdf (993.5 kB)
  • 897
    An Adenovirus Based Influenza Tablet Vaccine Induces Dose Dependent T Cell Responses
    Wendy Peters, PhD ; Jennifer Brandl, BS ; Josefina Martinez, Certificate in Biotechnology ; Leesun Kim, PhD ; Sean Tucker, PhD
    898
    GEN-003 Phase 2 Interim Results:  Therapeutic Vaccine for Genital Herpes Significantly Reduces Viral Shedding and Genital Lesions
    Nicholas Van Wagoner, MD, PhD ; William Koltun, MD ; Gregg Lucksinger, MD ; Terri Warren, ANP ; Stephen Tyring, MD, PhD, FIDSA ; David Bernstein, MD, FIDSA ; Peter Leone, MD ; Lori Panther, MD, MPH ; Jacob Lalezari, MD ; Kenneth Fife, MD, PhD, FIDSA ; Richard Novak, MD ; Richard Beigi, MD, MSc. ; John Kriesel, MD ; Jason Chan, PhD ; Sybil Tasker, MD, FIDSA ; Seth Hetherington, MD ; Anna Wald, MD, MPH, FIDSA
    Posters
  • ID Week Poster 898.VW.pdf (209.3 kB)
  • 899
    A Phase I Safety and Immunogenicity Dose Escalation Trial of Plague Vaccine, Flagellin/F1/V, In Healthy Adult Volunteers (DMID 08-0066)
    Sharon E Frey, MD ; Kathleen Lottenbach, MS ; Irene Graham, MD ; Edwin Anderson, MD ; Kanwaldeep Bajwa, MPH ; Ryan May, PhD ; Steven B Mizel, PhD ; Aaron H Graff, BS ; Robert B Belshe, MD
    902
    Renal Impairment and Clinical Outcomes of Tedizolid and Linezolid in Two Randomized Trials
    Pamela Moise, PharmD ; Natasha Broyde, MS ; Steven Anuskiewicz, MS ; Benjamin Miller, PharmD ; Taylor Sandison, MD ; Philippe Prokocimer, MD
    903
    A Prospective Phase 3 Trial of Boceprevir/Pegylated Interferon/Ribavirin for HCV/HIV Coinfected Persons
    Kenneth Sherman, MD ; Minhee Kang, MS, PhD ; Richard Sterling, MD ; Triin Umbleja, MSc ; Kristen M. Marks, MD ; Beverly Alston-Smith, MD ; Wayne Greaves, MD ; Adeel Butt, MD, MS
    904
    12 Weeks of Daclatasvir in Combination With Sofosbuvir for HIV/HCV Coinfection (ALLY-2 Study): Efficacy and Safety by Black Race
    Joseph Gathe, MD ; Dawn Fishbein, MD, MS ; Anthony Mills, MD ; Yue Zhao, MD, PhD. ; Stephanie Noviello, MD ; Peter Ackerman, MD
    905
    Early Innate and Adaptive Immune Responses to Investigational Human Immunodeficiency Virus (HIV)-1 Vaccines (VRC 016 study)
    Uzma Sarwar, MD ; Laura Novik, RN ; Mary Enama, M.A., PA-C ; Douglas Herrin, B.S. ; Sandeep Narpala, M.S. ; Adrian Mcdermott, M.Sc., PhD ; Barney S. Graham, MD, PhD, FIDSA ; Julie Ledgerwood, D.O.
    906
    Atazanavir plus Cobicistat (ATV+c) versus Atazanavir plus Ritonavir (ATV+r), Both in Combination with Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF): Week 48 Subgroup Analysis of a Phase 3, Randomized, Double-Blind, Active-Controlled Trial
    Edwin Dejesus, MD, FACP, FIDSA ; Joel Gallant, MD, MPH, FIDSA ; Peter Shalit, MD, PhD ; Huyen Cao, MD ; Ya-Pei Liu, PhD ; Joel Myers, MPharm ; Lisa Rosenblatt, MD, MPH ; Lingfeng Yang, PhD, MPH ; Javier Szwarcberg, MD, MPH
    Posters
  • Poster 906_DeJesus.pdf (2.8 MB)
  • 907
    The Use of Home-Based Telepsychiatry for Mild to Moderate Major Depression in HIV-Positive Adults 50 Years and Older Living in San Francisco
    Jessica Rhee, BA ; Eric Chan, MD ; Paul Elizondo III, DO ; James Bourgeois, OD, MD ; Cameron Foreman, BA ; Lisa Dazols, LCSW ; Jorien Breur, MD ; Joseph Shemuel, BA ; Amanda Martin, MSW ; Sharonya Shrivastava, BA ; Malcolm John, MD, MPH
    908
    Stable caloric intake and continued virologic suppression for HIV positive antiretroviral treatment (ART) experienced women after switching to fixed dose combination (FDC) of Emtricitabine (FTC), Tenofovir (TDF) and Rilpivirine (RPV)
    Prema Menezes, Ph D ; Katie Mollan, MS ; Erin Hoffman, BS ; Parker Xie, BS ; Jennifer Wills, RDN ; Cheryl Marcus, MSN ; John Rublein, pharm d ; Michael G. Hudgens, PhD ; Joseph Eron, MD
    911
    A Phase 1, Open-Label, Evaluation of the Single-Dose Pharmacokinetics of Delafloxacin (DLX) in Subjects With and Without Hepatic Impairment
    Randall Hoover, Ph.D. ; Megan Quintas, BA ; Laura Lawrence, BS ; Sriram Gunda, Ph.D. ; Eugene Sun, MD ; Sue Cammarata, MD
    912
    Phase 1 study evaluating safety, tolerability, pharmacokinetics and immunogenicity of REGN2222 in healthy adults: a new human monoclonal RSV-F antibody for RSV prevention
    Sumathi Sivapalasingam, MD ; David Caballero-Perez, PhD ; Matthew Houghton, MS ; Feng Yang, PhD ; John Davis, PhD ; Bo Gao, PhD ; Gregory Geba, MD

    CME Credits:

    ACPE Credits:

    ACPE Number:


    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 7th with the exception of research findings presented at the IDWeek press conferences.